SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Recent discussions around DJT are buzzing with political undertones, touching on topics from border security and immigration to trade relations. Community sentiment appears divided, with some users expressing concerns about potential impacts on American ranchers and farmers. The stock's performance and broader implications of political events remain central to the conversation.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending, with community members discussing its price action and potential. There is chatter about exchange-traded funds (ETFs), with Fidelity recently listing Solana. Some users are highlighting Solana's ecosystem and potential for future growth.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as the community rallies around its resilient development team and utility-focused roadmap, highlighting staking opportunities and the Broke Perspective media platform. Despite market dips, the community expresses conviction, emphasizing long-term building and the potential for significant gains. Discussions also involve collaborations and support from other Solana-based projects.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

NBIS is trending due to a sharp rebound after a significant decline, with community members debating whether the bottom has been reached and discussing potential catalysts like earnings and partnerships. The stock's connection to the AI infrastructure boom and recent news regarding accelerated power hookups for data centers are also fueling interest. Bullish investors are highlighting the company's long-term potential and the increasing demand for AI infrastructure.

Lumen Technologies, Inc. is an investment holding company, which engages in the provision of integrated communications to residential and business customers. It operates through the Business and Mass Markets segments. The Business segment provides products and services under four sales channels to enterprise and commercial customers. The Mass Markets segment focuses on consumer and small business customers. The company was founded in 1930 and is headquartered in Monroe, LA.

Lumen Technologies Inc

Lumen Technologies is trending as investors discuss its potential role in AI infrastructure, particularly following a $200M deal with Palantir that has sparked optimism. Community members are focused on Lumen's fiber optic network and data center connectivity, anticipating significant growth and a possible turnaround for the company. Bullish sentiment is building, with many expressing confidence in Lumen's long-term prospects within the evolving AI landscape.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai is trending as investors discuss its AI-powered biometric platform being deployed at Chicago O'Hare International Airport, sparking speculation about further airport security contracts and a potential TSA deal. The community is also focused on the company's large short interest and upcoming earnings, with some anticipating a squeeze. Bullish sentiment is fueled by the company's advancements in AI and its potential for significant growth within the national security sector.

$BALLIN is the perfect meme for everyone showing up every single day.  To be BALLIN, you gotta B-All-In.  The meaning to B All In doesn't only apply to the funds you invest.  It's about dedication.   The countless hours of research.   The endless raiding and working for your bags.  Not knowing how to quit while everyone is telling you you're wrong.  It's about believing in something.  Keep $BALLIN

B All In

$BALLIN is gaining attention, with community members highlighting its availability on Phantom Wallet and touting potential gains. The conversation centers around 'bags,' 'moonshots,' and 'rocket mode,' with many suggesting it's an opportune time to get in early. Some users are expressing concerns and caution.

USDC is a fully collateralized US dollar stablecoin. USDC is the bridge between dollars and trading on cryptocurrency exchanges. The technology behind CENTRE makes it possible to exchange value between people, businesses and financial institutions just like email between mail services and texts between SMS providers. We believe by removing artificial economic borders, we can create a more inclusive global economy.

USD Coin

USD Coin is trending amid discussions around stablecoin regulation and increasing adoption, particularly on Solana. Community members are highlighting its use in remittances, DeFi, and as a hedge against inflation in emerging markets. The meme coin BrokeCoin is also garnering attention within the USDC conversation.

The 401jk (just kidding) meme is a satirical punch in the gut in the face of the concept of retirement and also the 401k. The 401k total holdings are valued at around $12 trillion USD and it is the most popular retirement savings plan in the US. As time passes forevermore true retirement, or as we like to call it real freedom will only become much harder and harder for people to attain.  Through meme fueled laser focus and cyperphunk ideology the 401jK meme retirement fund token and community aim to point out the absurdities of how rigged our current system is, and how only insiders and those with power are starting the benefit from the increased centralization of cryptocurrency.........while also aiming to flip the $12 trillion USD 401k system to achieve freedom before our backs and knees are breaking.

401jK

401JK is trending as community members rally around its narrative of disrupting traditional retirement plans, with many expressing bullish sentiment and highlighting the project's strong community and organic growth on the $SOL blockchain. Discussions revolve around the token's potential to reach new all-time highs and offer an alternative path to financial freedom, contrasting it with perceived flaws in the traditional 401(k) system. The community is actively promoting its message and celebrating milestones, with a focus on long-term vision rather than short-term gains.

MUSE

MUSE is trending as traders discuss its limited coin supply and potential for a squeeze, drawing comparisons to past rallies and other low-cap cryptos. Community members are actively watching volume, speculating on price movements, and highlighting its potential within the NFT space. Some believe that with increased exposure, MUSE could see significant gains.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SpringWorks Gets CHMP Nod for Mirdametinib in Rare Disease

Shares of SpringWorks Therapeutics Inc. ended over 9% higher on Thursday following a report that the company is inching closer to getting acquired by an established giant, triggering a jump in discussions among retail traders.During regular trading hours on Thursday, The Wall Street Journal reported that Merck KGaA is nearing a $3.5 billion deal to acquire SpringWorks, which specializes in rare diseases and cancer.The report, citing people familiar with the matter, noted that the German giant had&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/swtx-stock-jumps-ahead-of-q4-2024-report/ch5uuz0RwZ">confirmed</a> in February that it was in advanced talks for the buyout, and the two parties have now agreed on a price close to $47 per share.After the closing bell, Merck <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.eqs-news.com/news/ad-hoc/merck-kgaa-merck-confirms-late-stage-discussions-with-springworks-therapeutics-inc-on-potential-acquisition/b6bde507-964a-46d9-846d-9d15390345d9_en">confirmed</a> the report, saying the two parties were discussing a deal at around $47 per share. However, it added that they had neither made any final decision nor entered into a legally binding agreement.On Stocktwits, sentiment for SpringWorks jumped into the 'extremely bullish' zone, accompanied by a 657% spike in message volume.<figure class="image"><img style="aspect-ratio:1318/316;" src="https://news.stocktwits-cdn.com/SWTX_sentiment_and_message_volume_as_of_April_24_png_712d46db30.webp" alt="SWTX sentiment and message volume as of April 24.png" width="1318" height="316"><figcaption>SWTX sentiment and message volume as of April 24. | source: Stocktwits</figcaption></figure>Several watchers appeared dissatisfied with the offer, indicating some alignment with the after-hours dip on Thursday."$47 is a joke, surely?" wrote one user, adding that Pfizer should throw its hat into the ring of prospective buyers.<stembedurl>https://stocktwits.com/monoksop/message/612643957</stembedurl>However, others expressed some relief."What I get, I get. Won't be super happy or anything, but I'll take the W and move on," said one watcher.<stembedurl>https://stocktwits.com/Son_of_Shango/message/612642003</stembedurl>SpringWorks has garnered interest from suitors thanks to its lead asset, Gomekli, which treats a rare genetic disorder that causes tumor growth in nerve tissue.The company's first FDA-approved drug, Ogsiveo, is already available in the U.S. for adult desmoid tumor patients requiring systemic treatment. It raked in $61.5 million in the fourth quarter of 2024.<a href="https://stocktwits.com/symbol/SWTX">SpringWorks' stock</a> has gained over 23% this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

A person examines financial data on a screen displaying a graph with upward and downward trends, using a pen to trace the line chart. | Representative Image: Getty Images

SpringWorks Therapeutics Retail Chatter Spikes As Germany’s Merck Confirms Late-Stage Talks For $3.5B Buyout

After the closing bell, Merck said the two parties were discussing a deal at around $47 per share.

Equity

After the closing bell, Merck said the two parties were discussing a deal at around $47 per share.


SpringWorks Therapeutics springs higher as Merck KGaA takeover said close

Investing.com -- Shares of  SpringWorks Therapeutics Inc  (NASDAQ:SWTX) surged higher Thursday afternoon on reports that a potential takeover of the company by Germany’s Merck KGaA (ETR:MRCG) is getting close.

Mineralys Therapeutics Inc. (123% jump in watchers)The clinical-stage biopharmaceutical company saw the highest jump in retail interest after reporting positive topline data from its Phase 3 and Phase 2 trials for lorundrostat in treating uncontrolled hypertension (uHTN) and resistant hypertension (rHTN). Both trials met their primary efficacy endpoints, showing statistically significant blood pressure reductions.&nbsp;The company also announced a $250 million underwritten public offering to fund lorundrostat’s development and pre-commercialization efforts.Mineralys stock is up over 15% year-to-date (YTD).Tenaya Therapeutics Inc. (11% jump in watchers)Tenaya saw increased attention after reporting stronger-than-expected fourth-quarter earnings and highlighting upcoming clinical data readouts for its gene therapy programs targeting cardiomyopathies.&nbsp;CEO Faraz Ali noted continued progress in the TN-201 MyPEAK-1 and TN-401 RIDGE-1 trials.&nbsp;Tenaya’s stock remains down over 53% YTD.SpringWorks Therapeutics Inc. (10% jump in watchers)SpringWorks gained traction amid ongoing&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/swtx-sees-biggest-weekly-biotech-jump-in-stocktwits-following/cheUZARRbb2">speculation</a> about a potential buyout by Merck KGaA. While Merck confirmed advanced merger discussions in its annual report, it stopped short of announcing a deal, leaving traders searching for clues. The company’s withdrawal from a Barclays healthcare conference further fueled speculation.&nbsp;SpringWorks stock is up more than 40% YTD.COSCIENS Biopharma Inc. (9% jump in watchers)COSCIENS initiated a Phase 2a clinical efficacy trial for its avenanthramides product, which is being explored for its anti-inflammatory properties. The trial, dubbed the AvenActive study, will assess safety and efficacy in two dosage arms.&nbsp;COSCIENS stock has gained over 20% YTD.Metagenomi Inc. (7% jump in watchers)Metagenomi published new research in Nature Communications on its novel CAST gene editing system, which enables precise, programmable integration of large gene cargoes. The technology could have major implications for treating genetic diseases like cystic fibrosis and Duchenne Muscular Dystrophy.&nbsp;Metagenomi stock is down more than 46% YTD.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Hand holding test tube over stock data on computer monitor. | Image source: Getty Images

Mineralys, Tenaya, SpringWorks, COSCIENS, Metagenomi: 5 Biotech Stocks That Led Retail Follower Growth Last Week

Positive data from clinical trials, earnings readouts, M&A speculation and new research drew heavy interest from retail traders on Stocktwits for these tickers for the week ended March 14, 2025.  

SpringWorks Therapeutics (SWTX) saw the biggest retail follower increase among biotech stocks last week on Stocktwits, even as its shares tumbled more than 14%, marking their worst weekly decline since mid-January.&nbsp;Despite the drop, retail sentiment flipped to 'bullish' from 'neutral,' driven by renewed speculation about German healthcare giant Merck KGaA (MKGAY) confirming details about a buyout.<figure class="image"><img style="aspect-ratio:1316/302;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/SWTX_sentiment_and_message_volume_March_10_cba5133a09.png" alt="SWTX sentiment and message volume March 10.png" width="1316" height="302"><figcaption>SWTX sentiment and message volume March 10. | source: Stocktwits</figcaption></figure>According to The Fly, Barclays analyst Peter Lawson noted that some investors had anticipated confirmation of an acquisition from Merck's earnings report last week.&nbsp;However, Merck's annual report, published Thursday, only acknowledged that discussions about a potential merger were at an advanced stage but stated that there was no certainty a deal would be signed.&nbsp;The absence of a definitive announcement left traders analyzing the language for clues.Adding to speculation, SpringWorks canceled its planned appearance at Barclays' healthcare conference this week, continuing a pattern of event withdrawals following the FDA approval of its lead drug, Gomekli, for treating neurofibromatosis type 1 (NF1).&nbsp;The company had previously backed out of an earnings call and another public event, fueling investor theories that a significant corporate development was underway.&nbsp;Barclays maintained an 'Overweight' rating on SpringWorks, with a price target of $63. It sees limited regulatory risk to a potential Merck buyout.Retail traders on Stocktwits reacted strongly to these developments. Message volumes surged, and the company's follower count increased by 17.9%, the highest among all biotech stocks last week.&nbsp;Some investors speculated that an acquisition could be announced this week, with one suggesting a potential offer price of $120 per share — a 140% premium to SpringWorks' last closing price.&nbsp;<stembedurl>https://stocktwits.com/Aombeus/message/607327621</stembedurl>Another pointed to Merck not disclosing a termination of negotiations, which German law would have allegedly required if talks had ended, and reaffirmed their belief in SpringWorks' leadership.<stembedurl>https://stocktwits.com/TheGunnerAB/message/607292647</stembedurl>According to Koyfin, short interest in SpringWorks has declined from 15.7% at the start of the year to 12.2% last week, suggesting that bearish bets against the stock have been easing.&nbsp;The company's shares currently trade at a 47% discount to the average analyst price target of $72.88. Five of the eight analysts covering SpringWorks have a ‘Buy’rating, while three rate it a ‘Strong Buy,’ according to Koyfin.Despite last week's sharp decline, SpringWorks remains up more than 36% year-to-date.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stockbroker analyzing financial stock market with reflection on eyeglasses. Photo via Westend61 on Getty Images

SpringWorks Therapeutics Leads Biotech Pack In Weekly Retail Follower Surge: What's Fueling Interest?

Investor attention is now on whether Merck will confirm a formal offer as speculation over a potential acquisition continues dominating discussions around the stock.

SpringWorks Therapeutics Inc. (SWTX) shares surged more than 10% in Wednesday’s after-hours, signaling strong investor optimism ahead of its quarterly earnings report due after the next session.The biopharmaceutical company, focused on treatments for rare diseases and cancer, is expected to report a narrowing of fourth-quarter (Q4) adjusted losses to $0.71 per share from $1.44 a year earlier.&nbsp;Meanwhile, revenue is projected to soar to $57.16 million from $5.4 million.On Stocktwits, sentiment remained firmly bullish, though message volumes dipped slightly.The stock’s retail following grew over 2% in the past week and more than 26% in the past month.Users noted that after-hours trading volumes spiked well above the daily average, signaling heightened interest.<stembedurl>https://stocktwits.com/patten1962/message/604919223</stembedurl>One trader posted: “Yet another sleepless night ahead. I hope this is the last, and we can all celebrate.”<stembedurl>https://stocktwits.com/StrangerTrades/message/604917416</stembedurl>Recent investor enthusiasm has been fueled by&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/swtx-stock-soars-on-acquisition-buzz/ch5EgKYRtu">reports</a> that German healthcare giant Merck KGaA is in advanced talks to acquire SpringWorks. While no official confirmation has been made, there are hopes that a potential deal could be signed in the coming weeks.Last week, BofA Securities raised its price target on SWTX to $87 from $65, maintaining a Buy rating. The research firm cited FDA approval for SpringWorks’ lead asset, Gomekli, as a key growth driver.Gomekli, a MEK inhibitor, treats neurofibromatosis type 1 (NF1), a rare genetic disorder that causes tumor growth in nerve tissue.In addition, SpringWorks’ first FDA-approved drug, Ogsiveo, is already available in the U.S. for adult desmoid tumor patients requiring systemic treatment. Last month, the company pre-announced Q4 U.S. Ogsiveo sales of $61.5 million.Despite the bullish momentum, short interest on SpringWorks stock climbed from 15.7% at the start of the year to 19.4% last week, according to Koyfin data.Still, SWTX shares have surged over 53% year-to-date, far outpacing the S&amp;P 500’s 4.7% gain.For updates and corrections, email newsroom[at]stocktwits[dot]com.

SpringWorks Therapeutics Gains Retail Interest Ahead Of Q4 Earnings – What Investors Expect

Recent investor enthusiasm has been fueled by reports that German healthcare giant Merck KGaA is in advanced talks to acquire SpringWorks.

SpringWorks Therapeutics and Jewelry Designer Jennifer Fisher Team Up to Encourage People with Desmoid Tumors to Take Action Before Their Tumor Takes Over

SpringWorks Therapeutics and Jewelry Designer Jennifer Fisher Team Up to Encourage People with Desmoid Tumors to Take Action Before Their Tumor Takes Over SpringWorks Therapeutics and Jewelry...

Springworks Therapeutics shares surged over 36% Monday, reaching levels last seen in mid-April 2022, as buyout speculation drove heavy trading.&nbsp;The stock is on track for its best day on record following a Reuters report that German healthcare and technology group Merck KGaA is in advanced talks to acquire the company, according to people familiar with the matter.&nbsp;If discussions are successful, a deal could be signed in the coming weeks, though neither Springworks nor Merck have commented on the report yet.Springworks is a commercial-stage biopharmaceutical company developing treatments for severe rare diseases and cancer.&nbsp;Ogsiveo, the company's first FDA-approved therapy, is used in the U.S. to treat adult patients with progressing desmoid tumors who require systemic treatment.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/SWTX_sentiment_and_message_volume_Feb_10_3b1f0e47dd.png" alt="SWTX sentiment and message volume Feb 10.png" width="1318" height="324"><figcaption>SWTX sentiment and message volume Feb 10 as of 12:10 pm ET | source: Stocktwits</figcaption></figure>On Stocktwits, sentiment for Springworks was 'extremely bullish' as message volume spiked, pushing the stock into the list of top trending symbols by late Monday morning.&nbsp;Retail traders flooded the platform with congratulatory messages for long-term holders, though some warned that a sharp pullback could occur if official statements refute the buyout rumors.<stembedurl>https://stocktwits.com/flanker30/message/603597464</stembedurl><stembedurl>https://stocktwits.com/AngusMacbeth/message/603598578</stembedurl>Last month, Springworks pre-announced fourth-quarter U.S. Ogsiveo sales of $61.5 million, exceeding TD Cowen's $57.0 million estimate and consensus expectations of $59.8 million. The brokerage had suggested that a buyout could be on the horizon.Springworks stock has risen 16% over the past 12 months. According to Koyfin data, its short interest stood at 18.4% as of the last check.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Springworks Stock Soars To Nearly 3-Year High On Buyout Buzz, Retail Sentiment Rockets

Reuters reported that German healthcare and technology group Merck KGaA is in advanced talks to acquire the company.

Springworks surges as Germany's Merck KGaA said to be targeting takeover

Investing.com -- Shares of Springworks Therapeutics (NASDAQ:SWTX) surged over 37% on Monday following reports that Germany’s  Merck  (NSE:PROR) KGaA is in advanced talks to acquire the U.S. biotech company, according to Reuters.

SpringWorks Therapeutics Stock Gets A RS Rating Lift

SpringWorks Therapeutics Stock Gets A RS Rating Lift...

Springworks Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the application of a medicine approach to acquiring, developing, and commercializing medicines. Its pipeline includes Nirogacestat, Mirdametinib, Brimarafenib, SW-682, and EGFR Inhibitor. The company was founded in August 2017 and is headquartered in Stamford, CT.

SWTX
SpringWorks Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SWTX News

SWTXSpringWorks Therapeutics Inc